{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:32:48Z","timestamp":1793305968113,"version":"4.5.0"},"reference-count":93,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:00:00Z","timestamp":1787961600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jlr.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Lipid Research"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jlr.2026.101137","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T06:44:00Z","timestamp":1788331440000},"page":"101137","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The monoacylglycerol acyltransferase 2 inhibitor VB-85387 reduces MASLD"],"prefix":"10.1016","volume":"67","author":[{"given":"Christina","family":"Gallo-Ebert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Wayne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9984-3056","authenticated-orcid":false,"suffix":"Jr.","given":"Joseph T.","family":"Nickels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jlr.2026.101137_bib1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jlr.2026.101137_bib2","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.54707","article-title":"Estimated burden of metabolic dysfunction-associated steatotic liver disease in US adults, 2020 to 2050","volume":"8","author":"Le","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.jlr.2026.101137_bib3","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1097\/HEP.0000000000000786","article-title":"Molecular mechanisms in MASLD\/MASH-related HCC","volume":"82","author":"Wang","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.jlr.2026.101137_bib4","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.cmet.2022.05.003","article-title":"Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer","volume":"34","author":"Huang","year":"2022","journal-title":"Cell Metab."},{"key":"10.1016\/j.jlr.2026.101137_bib5","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s40265-024-02045-0","article-title":"Resmetirom: first approval","volume":"84","author":"Keam","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.jlr.2026.101137_bib6","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1097\/HEP.0000000000001608","article-title":"Semaglutide therapy for metabolic dysfunction-associated steatohepatitis: november 2025 updates to AASLD Practice Guidance","volume":"83","author":"Bansal","year":"2026","journal-title":"Hepatology"},{"key":"10.1016\/j.jlr.2026.101137_bib7","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1159\/000539371","article-title":"EASL-EASD-EASO Clinical Practice Guidelines on the management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)","volume":"17","year":"2024","journal-title":"Obes. Facts"},{"key":"10.1016\/j.jlr.2026.101137_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2025.118731","article-title":"Comparative safety and side effects of semaglutide and tirzepatide: implications for clinical decision-making in obesity management","volume":"193","author":"Fahim","year":"2025","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.jlr.2026.101137_bib9","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/hep4.1657","article-title":"Effects of Resmetirom on noninvasive endpoints in a 36-Week phase 2 active treatment extension Study in patients with NASH","volume":"5","author":"Harrison","year":"2021","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.jlr.2026.101137_bib10","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jlr.2026.101137_bib11","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa2401755","article-title":"A phase 2 randomized trial of survodutide in MASH and fibrosis","volume":"391","author":"Sanyal","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jlr.2026.101137_bib12","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.cgh.2023.04.011","article-title":"Pegbelfermin in patients with Nonalcoholic steatohepatitis and stage 3 fibrosis (FALCON 1): a randomized phase 2b Study","volume":"22","author":"Loomba","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jlr.2026.101137_bib13","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1056\/NEJMoa2502242","article-title":"Efruxifermin in compensated liver cirrhosis caused by MASH","volume":"392","author":"Noureddin","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jlr.2026.101137_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2024.103910","article-title":"NAFLD and NASH: etiology, targets and emerging therapies","volume":"29","author":"Wei","year":"2024","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jlr.2026.101137_bib15","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1002\/hep.31843","article-title":"Saroglitazar, a PPAR-alpha\/gamma agonist, for treatment of NAFLD: a randomized controlled double-blind phase 2 trial","volume":"74","author":"Gawrieh","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jlr.2026.101137_bib16","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1097\/HEP.0000000000001475","article-title":"Chiglitazar in MASLD with hypertriglyceridemia and insulin resistance: a phase II, randomized, double-blind, placebo-controlled study","volume":"83","author":"Sun","year":"2026","journal-title":"Hepatology"},{"key":"10.1016\/j.jlr.2026.101137_bib17","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.jhep.2024.12.045","article-title":"Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD","volume":"82","author":"Barb","year":"2025","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jlr.2026.101137_bib18","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1097\/HEP.0000000000001254","article-title":"Comparison of pharmacological therapies in metabolic dysfunction-associated steatohepatitis for fibrosis regression and MASH resolution: systematic review and network meta-analysis","volume":"82","author":"Souza","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.jlr.2026.101137_bib19","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1016\/j.cmet.2022.10.007","article-title":"MGAT2 inhibitor decreases liver fibrosis and inflammation in murine NASH models and reduces body weight in human adults with obesity","volume":"34","author":"Cheng","year":"2022","journal-title":"Cell Metab."},{"key":"10.1016\/j.jlr.2026.101137_bib20","doi-asserted-by":"crossref","first-page":"8512","DOI":"10.1073\/pnas.132274899","article-title":"Identification of a gene encoding MGAT1, a monoacylglycerol acyltransferase","volume":"99","author":"Yen","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jlr.2026.101137_bib21","doi-asserted-by":"crossref","first-page":"13860","DOI":"10.1074\/jbc.M300139200","article-title":"Cloning and functional characterization of a mouse intestinal acyl-CoA:monoacylglycerol acyltransferase, MGAT2","volume":"278","author":"Cao","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jlr.2026.101137_bib22","doi-asserted-by":"crossref","first-page":"18532","DOI":"10.1074\/jbc.M301633200","article-title":"MGAT2, a monoacylglycerol acyltransferase expressed in the small intestine","volume":"278","author":"Yen","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jlr.2026.101137_bib23","doi-asserted-by":"crossref","first-page":"13611","DOI":"10.1074\/jbc.C300042200","article-title":"Identification of acyl coenzyme a:monoacylglycerol acyltransferase 3, an intestinal specific enzyme implicated in dietary fat absorption","volume":"278","author":"Cheng","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jlr.2026.101137_bib24","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1194\/jlr.R052902","article-title":"Intestinal triacylglycerol synthesis in fat absorption and systemic energy metabolism","volume":"56","author":"Yen","year":"2015","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.jlr.2026.101137_bib25","doi-asserted-by":"crossref","first-page":"25657","DOI":"10.1074\/jbc.M302835200","article-title":"Properties of the mouse intestinal acyl-CoA:monoacylglycerol acyltransferase, MGAT2","volume":"278","author":"Cao","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jlr.2026.101137_bib26","doi-asserted-by":"crossref","first-page":"E927","DOI":"10.1152\/ajpendo.00179.2003","article-title":"Human intestinal monoacylglycerol acyltransferase: differential features in tissue expression and activity","volume":"285","author":"Lockwood","year":"2003","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.jlr.2026.101137_bib27","doi-asserted-by":"crossref","first-page":"18878","DOI":"10.1074\/jbc.M313272200","article-title":"A predominant role of acyl-CoA:monoacylglycerol acyltransferase-2 in dietary fat absorption implicated by tissue distribution, subcellular localization, and up-regulation by high fat diet","volume":"279","author":"Cao","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jlr.2026.101137_bib28","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1194\/jlr.P025536","article-title":"Evidence for regulated monoacylglycerol acyltransferase expression and activity in human liver","volume":"53","author":"Hall","year":"2012","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.jlr.2026.101137_bib29","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1194\/jlr.M016840","article-title":"Deficiency of MGAT2 increases energy expenditure without high-fat feeding and protects genetically obese mice from excessive weight gain","volume":"52","author":"Nelson","year":"2011","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.jlr.2026.101137_bib30","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/nm.1937","article-title":"Deficiency of the intestinal enzyme acyl coa:monoacylglycerol acyltransferase-2 protects mice from metabolic disorders induced by high-fat feeding","volume":"15","author":"Yen","year":"2009","journal-title":"Nat. Med."},{"key":"10.1016\/j.jlr.2026.101137_bib31","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1194\/jlr.M035493","article-title":"Intestine-specific expression of MOGAT2 partially restores metabolic efficiency in Mogat2-deficient mice","volume":"54","author":"Gao","year":"2013","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.jlr.2026.101137_bib32","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1194\/jlr.M055228","article-title":"Adult-onset deficiency of acyl coa:monoacylglycerol acyltransferase 2 protects mice from diet-induced obesity and glucose intolerance","volume":"56","author":"Banh","year":"2015","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.jlr.2026.101137_bib33","doi-asserted-by":"crossref","first-page":"13135","DOI":"10.1021\/acs.jmedchem.3c01147","article-title":"Discovery of 12 (BMS-986172) as a highly potent MGAT2 inhibitor that achieved targeted efficacious exposures at a low human dose for the treatment of metabolic disorders","volume":"66","author":"Meng","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jlr.2026.101137_bib34","doi-asserted-by":"crossref","first-page":"9879","DOI":"10.1021\/acs.jmedchem.8b00864","article-title":"Monoacylglycerol acyltransferase 2 (MGAT2) inhibitors for the treatment of metabolic diseases and nonalcoholic steatohepatitis (NASH)","volume":"61","author":"Devasthale","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jlr.2026.101137_bib35","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/2211-5463.12778","article-title":"Inhibition of MGAT2 modulates fat-induced gut peptide release and fat intake in normal mice and ameliorates obesity and diabetes in ob\/ob mice fed on a high-fat diet","volume":"10","author":"Mochida","year":"2020","journal-title":"FEBS Open Bio"},{"key":"10.1016\/j.jlr.2026.101137_bib36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0150976","article-title":"Pharmacological inhibition of monoacylglycerol O-Acyltransferase 2 improves hyperlipidemia, obesity, and diabetes by change in intestinal fat utilization","volume":"11","author":"Take","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jlr.2026.101137_bib37","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.3748\/wjg.v26.i17.1993","article-title":"Metabolic inflammation as an instigator of fibrosis during non-alcoholic fatty liver disease","volume":"26","author":"Katsarou","year":"2020","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.jlr.2026.101137_bib38","article-title":"Adipose tissue and adipokines: the association with and application of adipokines in obesity","volume":"2014","author":"Khan","year":"2014","journal-title":"Scientifica (Cairo)"},{"key":"10.1016\/j.jlr.2026.101137_bib39","first-page":"101","article-title":"Kupffer cell metabolism and function","volume":"1","author":"Nguyen-Lefebvre","year":"2015","journal-title":"J. Enzymol. Metab."},{"key":"10.1016\/j.jlr.2026.101137_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2023.1199519","article-title":"Activation of Kupffer cells in NAFLD and NASH: mechanisms and therapeutic interventions","volume":"11","author":"Xu","year":"2023","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.jlr.2026.101137_bib41","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: from bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal. Transduct. Target Ther."},{"key":"10.1016\/j.jlr.2026.101137_bib42","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adz3223","article-title":"Decoding the CHI3L1\/IL-13Ralpha2 signaling nexus in MASH-fibrosis pathogenesis","volume":"11","author":"Zheng","year":"2025","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jlr.2026.101137_bib43","doi-asserted-by":"crossref","first-page":"33676","DOI":"10.1074\/jbc.M204204200","article-title":"Interleukin-22 (IL-22) activates the JAK\/STAT, ERK, JNK, and p38 MAP kinase pathways in a rat hepatoma cell line. Pathways that are shared with and distinct from IL-10","volume":"277","author":"Lejeune","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jlr.2026.101137_bib44","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1186\/s12944-020-01425-1","article-title":"Hepatic lipid profile in mice fed a choline-deficient, low-methionine diet resembles human non-alcoholic fatty liver disease","volume":"19","author":"Haberl","year":"2020","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.jlr.2026.101137_bib45","first-page":"2649","article-title":"Chemerin in a mouse model of non-alcoholic steatohepatitis and hepatocarcinogenesis","volume":"38","author":"Haberl","year":"2018","journal-title":"Anticancer Res."},{"key":"10.1016\/j.jlr.2026.101137_bib46","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3390\/cancers16020259","article-title":"MASLD and the development of HCC: pathogenesis and therapeutic challenges","volume":"16","author":"Phoolchund","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jlr.2026.101137_bib47","doi-asserted-by":"crossref","first-page":"14773","DOI":"10.1021\/acs.jmedchem.1c01356","article-title":"Screening hit to clinical candidate: discovery of BMS-963272, a potent, selective MGAT2 inhibitor for the treatment of metabolic disorders","volume":"64","author":"Turdi","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jlr.2026.101137_bib48","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1089\/ten.tec.2017.0018","article-title":"A modified hydroxyproline assay based on hydrochloric acid in ehrlich's solution accurately measures tissue collagen content","volume":"23","author":"Cissell","year":"2017","journal-title":"Tissue Eng. Part C Methods"},{"key":"10.1016\/j.jlr.2026.101137_bib49","article-title":"Liver fibrosis in non-alcoholic fatty liver disease: from liver biopsy to non-invasive biomarkers in diagnosis and treatment","volume":"8","author":"Heyens","year":"2021","journal-title":"Front. Med. (Lausanne)"},{"key":"10.1016\/j.jlr.2026.101137_bib50","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/hep.24127","article-title":"Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings","volume":"53","author":"Brunt","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jlr.2026.101137_bib51","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/B978-0-12-411619-1.00006-9","article-title":"Quantifying size and number of adipocytes in adipose tissue","volume":"537","author":"Parlee","year":"2014","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.jlr.2026.101137_bib52","doi-asserted-by":"crossref","DOI":"10.1002\/osp4.70131","article-title":"The human monoacylglycerol acyltransferase 2 inhibitor VB-85387 is associated with weight loss in mice with obesity","volume":"12","author":"Corbalan","year":"2026","journal-title":"Obes. Sci. Pract."},{"key":"10.1016\/j.jlr.2026.101137_bib53","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2025.1567573","article-title":"Sex differences in diet-induced MASLD - are female mice naturally protected?","volume":"16","author":"Meyer","year":"2025","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.jlr.2026.101137_bib54","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1136\/gutjnl-2020-323323","article-title":"Integrative study of diet-induced mouse models of NAFLD identifies PPARalpha as a sexually dimorphic drug target","volume":"71","author":"Smati","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.jlr.2026.101137_bib55","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/s41467-022-28138-6","article-title":"Formyl peptide receptor 2 determines sex-specific differences in the progression of nonalcoholic fatty liver disease and steatohepatitis","volume":"13","author":"Lee","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jlr.2026.101137_bib56","doi-asserted-by":"crossref","first-page":"G51","DOI":"10.1152\/ajpgi.00110.2024","article-title":"Characterization of six clinical drugs and dietary intervention in the nonobese CDAA-HFD mouse model of MASH and progressive fibrosis","volume":"328","author":"Nielsen","year":"2025","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.jlr.2026.101137_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2024.100695","article-title":"Humanized monoacylglycerol acyltransferase 2 mice develop metabolic dysfunction-associated steatohepatitis","author":"Corbalan","year":"2024","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.jlr.2026.101137_bib58","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s42255-024-01043-6","article-title":"An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"6","author":"Vacca","year":"2024","journal-title":"Nat. Metab."},{"key":"10.1016\/j.jlr.2026.101137_bib59","article-title":"Lipid metabolism in MASLD and MASH: from mechanism to the clinic","volume":"6","author":"Carli","year":"2024","journal-title":"JHEP Rep."},{"key":"10.1016\/j.jlr.2026.101137_bib60","doi-asserted-by":"crossref","DOI":"10.1172\/JCI186420","article-title":"MASH: the nexus of metabolism, inflammation, and fibrosis","volume":"135","author":"Steinberg","year":"2025","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jlr.2026.101137_bib61","first-page":"371","article-title":"Update on clinical trials for nonalcoholic steatohepatitis","volume":"19","author":"Nathani","year":"2023","journal-title":"Gastroenterol. Hepatol. (N Y)"},{"key":"10.1016\/j.jlr.2026.101137_bib62","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.tips.2020.12.001","article-title":"Triglycerides in nonalcoholic fatty liver disease: guilty until proven innocent","volume":"42","author":"Semova","year":"2021","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.jlr.2026.101137_bib63","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.4254\/wjh.v13.i11.1688","article-title":"Abnormal liver enzymes: a review for clinicians","volume":"13","author":"Kalas","year":"2021","journal-title":"World J. Hepatol."},{"key":"10.1016\/j.jlr.2026.101137_bib64","doi-asserted-by":"crossref","first-page":"596","DOI":"10.2174\/1389203717666151201192247","article-title":"Hydroxyproline: a potential biochemical marker and its role in the pathogenesis of different diseases","volume":"17","author":"Srivastava","year":"2016","journal-title":"Curr. Protein Pept. Sci."},{"key":"10.1016\/j.jlr.2026.101137_bib65","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1002\/j.2040-4603.2013.tb00529.x","article-title":"Hepatic stellate cells and liver fibrosis","volume":"3","author":"Puche","year":"2013","journal-title":"Compr. Physiol."},{"key":"10.1016\/j.jlr.2026.101137_bib66","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/S1542-3565(04)00616-0","article-title":"Hepatic stellate cells and fibrosis progression in patients with nonalcoholic fatty liver disease","volume":"3","author":"Feldstein","year":"2005","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jlr.2026.101137_bib67","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1097\/HEP.0000000000001511","article-title":"PPARidgm shifts in the treatment of metabolic dysfunction-associated steatotic liver disease","volume":"83","author":"Abushamat","year":"2026","journal-title":"Hepatology"},{"key":"10.1016\/j.jlr.2026.101137_bib68","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1194\/jlr.M100417-JLR200","article-title":"Transcriptional activities of nuclear SREBP-1a, -1c, and -2 to different target promoters of lipogenic and cholesterogenic genes","volume":"43","author":"Amemiya-Kudo","year":"2002","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.jlr.2026.101137_bib69","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-72217-1","article-title":"Maid gene dysfunction promotes hyperobesity via the reduction of adipose tissue inflammation in Mc4r gene-deficient mice","volume":"14","author":"Koyama","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jlr.2026.101137_bib70","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41392-024-01757-9","article-title":"NF-kappaB in biology and targeted therapy: new insights and translational implications","volume":"9","author":"Guo","year":"2024","journal-title":"Signal. Transduct. Target Ther."},{"key":"10.1016\/j.jlr.2026.101137_bib71","article-title":"Beyond antagonism: IL-4 exploits TNF signaling to shape its gene expression signature in monocytes and macrophages","author":"Yuan","year":"2025","journal-title":"bioRxiv"},{"key":"10.1016\/j.jlr.2026.101137_bib72","doi-asserted-by":"crossref","first-page":"7566","DOI":"10.1074\/jbc.273.13.7566","article-title":"Tumor necrosis factor-alpha induces interleukin-6 production and integrin ligand expression by distinct transduction pathways","volume":"273","author":"De Cesaris","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jlr.2026.101137_bib73","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1159\/000320556","article-title":"TNF increases expression of IL-4 and PARs in mast cells","volume":"26","author":"Zhang","year":"2010","journal-title":"Cell Physiol. Biochem."},{"key":"10.1016\/j.jlr.2026.101137_bib74","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jceh.2019.09.006","article-title":"NonInvasive biomarkers in nonalcoholic fatty liver disease: are we there yet?","volume":"10","author":"Singh","year":"2020","journal-title":"J. Clin. Exp. Hepatol."},{"key":"10.1016\/j.jlr.2026.101137_bib75","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1494110","article-title":"IL-6 augments IL-4-induced polarization of primary human macrophages through synergy of STAT3, STAT6 and BATF transcription factors","volume":"7","author":"Gupta","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jlr.2026.101137_bib76","doi-asserted-by":"crossref","first-page":"197","DOI":"10.7570\/jomes23052","article-title":"Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): a state-of-the-art review","volume":"32","author":"Chan","year":"2023","journal-title":"J. Obes. Metab. Syndr."},{"key":"10.1016\/j.jlr.2026.101137_bib77","first-page":"93","article-title":"Role of perturbated hemostasis in MASLD and its correlation with adipokines","volume":"14","author":"Pezzino","year":"2024","journal-title":"Life (Basel)"},{"key":"10.1016\/j.jlr.2026.101137_bib78","doi-asserted-by":"crossref","DOI":"10.3390\/biom14040476","article-title":"Innate immunity and MASLD","volume":"14","author":"Meyer","year":"2024","journal-title":"Biomolecules"},{"key":"10.1016\/j.jlr.2026.101137_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexmp.2021.104733","article-title":"TGF-beta1 signaling can worsen NAFLD with liver fibrosis backdrop","volume":"124","author":"Ahmed","year":"2022","journal-title":"Exp. Mol. Pathol."},{"key":"10.1016\/j.jlr.2026.101137_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105739","article-title":"Hepatic stellate cells role in the course of metabolic disorders development - a molecular overview","volume":"170","author":"Bourebaba","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.jlr.2026.101137_bib81","article-title":"The microenvironment in the development of MASLD-MASH-HCC and associated therapeutic in MASH-HCC","volume":"16","author":"Wu","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jlr.2026.101137_bib82","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/imm.13943","article-title":"The roles of T cells in the development of metabolic dysfunction-associated steatohepatitis","volume":"176","author":"Ge","year":"2025","journal-title":"Immunology"},{"key":"10.1016\/j.jlr.2026.101137_bib83","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.cmet.2018.10.012","article-title":"Preclinical models for studying NASH-driven HCC: how useful are they?","volume":"29","author":"Febbraio","year":"2019","journal-title":"Cell Metab."},{"key":"10.1016\/j.jlr.2026.101137_bib84","doi-asserted-by":"crossref","DOI":"10.1242\/jeb.164970","article-title":"Adipose morphology and metabolic disease","volume":"221","author":"Tandon","year":"2018","journal-title":"J. Exp. Biol."},{"key":"10.1016\/j.jlr.2026.101137_bib85","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1113\/EP092001","article-title":"The ins and outs of liver fat metabolism: the effect of phenotype and diet on risk of intrahepatic triglyceride accumulation","volume":"110","author":"Smith","year":"2025","journal-title":"Exp. Physiol."},{"key":"10.1016\/j.jlr.2026.101137_bib86","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.bbalip.2011.09.010","article-title":"Fatty acid transport proteins, implications in physiology and disease","volume":"1821","author":"Kazantzis","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.jlr.2026.101137_bib87","doi-asserted-by":"crossref","first-page":"17338","DOI":"10.1074\/jbc.M114.555961","article-title":"Intestine-specific deletion of acyl-CoA:monoacylglycerol acyltransferase (MGAT) 2 protects mice from diet-induced obesity and glucose intolerance","volume":"289","author":"Nelson","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jlr.2026.101137_bib88","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1194\/jlr.M084947","article-title":"Metabolic importance of adipose tissue monoacylglycerol acyltransferase 1 in mice and humans","volume":"59","author":"Liss","year":"2018","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.jlr.2026.101137_bib89","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0043962","article-title":"Over-expression of monoacylglycerol lipase (MGL) in small intestine alters endocannabinoid levels and whole body energy balance, resulting in obesity","volume":"7","author":"Chon","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jlr.2026.101137_bib90","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1194\/jlr.M058586","article-title":"Global deletion of MGL in mice delays lipid absorption and alters energy homeostasis and diet-induced obesity","volume":"56","author":"Douglass","year":"2015","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.jlr.2026.101137_bib91","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1096\/fj.201801203R","article-title":"Monoacylglycerol lipase deficiency affects diet-induced obesity, fat absorption, and feeding behavior in CB(1) cannabinoid receptor-deficient mice","volume":"33","author":"Yoshida","year":"2019","journal-title":"FASEB J."},{"key":"10.1016\/j.jlr.2026.101137_bib92","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.2337\/db08-1237","article-title":"GPR119 is essential for oleoylethanolamide-induced glucagon-like peptide-1 secretion from the intestinal enteroendocrine L-cell","volume":"58","author":"Lauffer","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.jlr.2026.101137_bib93","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1194\/jlr.M800116-JLR200","article-title":"Metabolism of apical versus basolateral sn-2-monoacylglycerol and fatty acids in rodent small intestine","volume":"49","author":"Storch","year":"2008","journal-title":"J. Lipid Res."}],"container-title":["Journal of Lipid Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022227526001677?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022227526001677?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:19:44Z","timestamp":1793305184000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022227526001677"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":93,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0022227526001677"],"URL":"https:\/\/doi.org\/10.1016\/j.jlr.2026.101137","relation":{},"ISSN":["0022-2275"],"issn-type":[{"value":"0022-2275","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The monoacylglycerol acyltransferase 2 inhibitor VB-85387 reduces MASLD","name":"articletitle","label":"Article Title"},{"value":"Journal of Lipid Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jlr.2026.101137","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc on behalf of American Society for Biochemistry and Molecular Biology.","name":"copyright","label":"Copyright"}],"article-number":"101137"}}